Anti-TNFR2 Agonistic Antibody

About Biolojic Design

Biolojic Design is a private, preclinical-stage biotech leveraging a proprietary AI/ML platform to engineer next-generation antibody therapeutics. The company's core innovation is designing 'programmable antibodies' that can act as dynamic functional switches, such as epitope-specific binders and symmetrical multi-specific 'Multibodies,' aiming for greater precision, efficacy, and lower toxicity. It has established key partnerships with Teva Pharmaceuticals and Johnson & Johnson Innovation (JLABS) and is advancing a pipeline targeting validated pathways in autoimmunity and cancer. The company is led by a team with expertise spanning computational biology, AI, and drug development.

Therapeutic Areas